相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
16.7%
已完成
1
16.7%
招募中
3
50.0%
终止
1
16.7%
暂无批准数据
- Verge Genomics has rebranded as Verge Labs and laid off 90% of its workforce after its AI-designed ALS drug VRG50635 failed in early-stage clinical trials. - The experimental drug, targeting the PIKfyve enzyme, showed increased levels of neurofilament light chain protein, indicating it wasn't having the desired therapeutic effect. - The company is pivoting from drug development to providing AI-driven data services for target identification, patient selection, and biomarker prediction. - CEO Alice Zhang emphasized that setbacks are expected with transformational technologies and that learnings will be fed back into the platform for iterative improvements.
• Verge Genomics has initiated Phase 1 clinical trials for VRG50635, a novel PIKfyve inhibitor discovered using their AI platform ConVERGE, marking a significant milestone in AI-driven drug development. • The drug candidate, developed in just four years, targets a novel mechanism involving lysosomal function in ALS, demonstrating promising neuron preservation effects in preclinical studies. • This achievement positions Verge Genomics among select companies successfully transitioning AI-discovered drugs to clinical trials, supported by major pharmaceutical investors including Eli Lilly and Merck & Co.
